BullFrog AI Holdings, Inc. Overview
Industry: Health Information Services
Sector: Healthcare
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
BullFrog AI Holdings, Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review BullFrog AI Holdings, Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
BullFrog AI Holdings, Inc. Competitors
BullFrog AI Holdings, Inc. operates in the Health Information Services industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans